Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 11:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 172 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Warfarin Clear all
Withdrawn Phase 4 Interventional

Evaluation of Wound Drainage After Knee or Hip Arthroplasty

NCT02054936
View directory record Official record
Conditions
Complications; Arthroplasty
Interventions
Rivaroxaban (Xarelto), Warfarin (Coumadin)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Phase 3 Interventional Results available

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

NCT00781391
View directory record Official record
Conditions
Stroke, Atrial Fibrillation, Embolism
Interventions
warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg), placebo warfarin, placebo edoxaban
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
21 Years and older
Enrollment
21,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
316
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Phase 3 Interventional Results available

Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial

NCT00041938
View directory record Official record
Conditions
Heart Disease, Stroke, Ischemic Heart Disease, Myocardial Infarction
Interventions
aspirin, Warfarin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
2,305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
54
States / cities
Tucson, Arizona • Santa Clara, California • West Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 9, 2026, 11:40 PM EDT
Not listed No phase listed Observational

The DARE Warfarin CER Study

NCT03271450
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days), Apixaban: extended treatment (e.g at least 90 days), Apixaban: extended treatment (e.g at least 180 days), Apixaban: extended treatment (e.g at least 270 days), Rivaroxaban: extended treatment (e.g at least 90 days), Rivaroxaban: extended treatment (e.g at least 180 days), Rivaroxaban: extended treatment (e.g at least 270 days), Edoxaban: extended treatment (e.g at least 90 days), Edoxaban: extended treatment (e.g at least 180 days), Edoxaban: extended treatment (e.g at least 270 days), Warfarin: extended treatment (e.g at least 90 days), Warfarin: extended treatment (e.g at least 180 days), Warfarin: extended treatment (e.g at least 270 days)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
416,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional

Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

NCT00448396
View directory record Official record
Conditions
Advanced Malignancies
Interventions
Patupilone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2009 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Phase 3 Interventional

Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation

NCT01006876
View directory record Official record
Conditions
Thromboembolism
Interventions
Coumadin
Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 9, 2026, 11:40 PM EDT
Terminated Phase 2 Interventional

Long Term Open Follow-up With H376/95 vs. Warfarin

NCT00206063
View directory record Official record
Conditions
Stroke Prevention in Patients With Atrial Fibrillation
Interventions
EXANTA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Oct 9, 2026, 11:40 PM EDT
Completed No phase listed Observational

Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data

NCT04818151
View directory record Official record
Conditions
Venous Thromboembolic Disease, Kidney Failure, Chronic
Interventions
Warfarin, Apixaban
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
14,914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male Subjects

NCT01657825
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of S- and R-warfarin, Pharmacodynamics of Warfarin, Healthy Volunteers
Interventions
Isavuconazole, Warfarin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2012 · Synced Oct 9, 2026, 11:40 PM EDT
Completed No phase listed Observational

Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling

NCT01964794
View directory record Official record
Conditions
Stable Target INR
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
60 Years to 69 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 9, 2026, 11:40 PM EDT
Recruiting Phase 4 Interventional

Vitamin K for Perioperative Warfarin Management

NCT07515664
View directory record Official record
Conditions
Anticoagulant Therapy
Interventions
Vitamin K, Warfarin (standard without loading), Warfarin (standard with loading)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Not applicable Interventional

Genotype-Guided Warfarin Therapy Trial

NCT00904293
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Artificial Heart Valve
Interventions
Genotype-guided dose determination, Non-genotype guided warfarin dosing
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Not applicable Interventional

Warfarin and Non-Steroidal Anti-Inflammatory Drugs (NSAID) Customized Alert

NCT00880932
View directory record Official record
Conditions
Warfarin and NSAID
Interventions
Electronic Alert
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
1,865 participants
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2009 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

NCT00504556
View directory record Official record
Conditions
Atrial Fibrillation, Thromboembolism
Interventions
Edoxaban (DU-176b), warfarin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
22
States / cities
Huntsville, Alabama • Anaheim, California • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Phase 4 Interventional Results available

Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation

NCT02608099
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Interrupted apixaban, Uninterrupted apixaban
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Huntsville, Alabama • Mission Viejo, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 9, 2026, 11:40 PM EDT
Completed No phase listed Observational

Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients

NCT03374540
View directory record Official record
Conditions
Nonvalvular Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
78,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Multiple Locations, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants

NCT01432938
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
dulaglutide, Warfarin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional

Treatment for Blood Clots in the Veins of the Legs

NCT00001713
View directory record Official record
Conditions
Embolism, Thrombophlebitis
Interventions
Recombinant Tissue Plasminogen Activator, Heparin, Warfarin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects

NCT02434861
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Digoxin, Sulfasalazine, Cooperstown Cocktail
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

NCT03363815
View directory record Official record
Conditions
Heathy Volunteer
Interventions
CC-90001, Omeprazole, Midazolam, Warfarin, Vitamin K, Rosuvastatin, Metformin, Digoxin, Nintedanib
Drug · Dietary Supplement
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

NCT02540668
View directory record Official record
Conditions
Healthy
Interventions
Lanabecestat, Warfarin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 9, 2026, 11:40 PM EDT
Active, not recruiting No phase listed Observational

On-X Aortic Prosthetic Heart Valve Low Dose Warfarin Post Approval Clinical Registry Study

NCT02677974
View directory record Official record
Conditions
Thrombotic and Bleeding Events
Interventions
On-X Aortic Heart Valve replacement
Device
Lead sponsor
On-X Life Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
15
States / cities
Tucson, Arizona • Hartford, Connecticut • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Phase 3 Interventional Results available

Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation

NCT03702582
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Rivaroxaban, Warfarin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects

NCT02567682
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 9, 2026, 11:40 PM EDT